Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.

Zangari, Maurizio

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. [electronic resource] - European journal of haematology Jun 2011 - 484-7 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article

1600-0609

10.1111/j.1600-0609.2011.01602.x doi


Alkaline Phosphatase--blood
Antineoplastic Agents--therapeutic use
Boronic Acids--therapeutic use
Bortezomib
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma--drug therapy
Oligopeptides--therapeutic use
Osteogenesis--drug effects
Protease Inhibitors--therapeutic use
Proteasome Inhibitors
Pyrazines--therapeutic use
Retrospective Studies
Treatment Outcome